Driving Clinical Success in Antibody-Drug Conjugates
Engineering Resilience - Expanding the Conjugate Toolkit
5/13/2027 - May 14, 2027 ALL TIMES EDT
ADCs have moved well past proof-of-concept, and with multiple conjugates now in development against overlapping targets, the field’s focus has shifted to designing for resilience. This track examines how resistance arises, including in the tumor microenvironment, and how it can be overcome through novel payload classes, dual-payload and multi-target formats, and smarter sequencing and combination strategies. It also looks beyond the conventional ADC to logic-gated designs, oligonucleotide and peptide conjugates, radioligands, and emerging RNA-based platforms. For discovery, translational, and clinical teams, this is where to benchmark which conjugate designs are gaining traction and which are still finding their footing.
Preliminary Agenda

PLENARY FIRESIDE CHAT

Panel Moderator:

PANEL DISCUSSION: From Discovery to Impact: Perspectives from a Patient Advocate and a Patient-Cohort Leader on Accelerating Therapeutic Innovation

Jane Osbourn, PhD, CEO, Alchemab Therapeutics Ltd. , CEO , Alchemab Therapeutics

Panelists:

Debra Miller, Founder & CEO, CureDuchenne , Founder & CEO , CureDuchenne

Craig Ritchie, PhD, CEO & Founder, Scottish Brain Sciences , Founder & CEO , Scottish Brain Sciences

OVERCOMING RESISTANCE: UNDERSTANDING MECHANISMS OF ACTION OF ADCs

ADCs in the Tumor Microenvironment: What Happens at Ground Zero to Make or Break Resistance?

Photo of Greg M. Thurber, PhD, Professor, Chemical Engineering & Biomedical Engineering, University of Michigan , Professor , Chemical Engineering & Biomedical Engineering , University of Michigan
Greg M. Thurber, PhD, Professor, Chemical Engineering & Biomedical Engineering, University of Michigan , Professor , Chemical Engineering & Biomedical Engineering , University of Michigan
Photo of Yanay Ofran, PhD, Founder, CEO, Biolojic Design Ltd. , Founder & CEO , Biolojic Design Ltd
Yanay Ofran, PhD, Founder, CEO, Biolojic Design Ltd. , Founder & CEO , Biolojic Design Ltd

Acquired resistance remains a major barrier to the clinical success of ADCs, and efforts to overcome it through novel payloads have delivered limited gains. A multibody is a standard IgG in which each Fab arm binds either of two targets in an OR-gate manner. We show that conjugating a validated payload to a multibody leads to better internalization and more robust cancer cell killing even in resistant tumors. We present the AI-driven design of BD200 and the in vitro and in vivo evidence for its ability to overcome resistance.

KEYNOTE PRESENTATION: Separating Signal from Noise—How to Manage a World with Several Hundred ADCs in Development

Photo of Anthony W. Tolcher, MD, FRCPC, FACP, CEO & Founder, NEXT Oncology , CEO & Founder , NEXT Oncology
Anthony W. Tolcher, MD, FRCPC, FACP, CEO & Founder, NEXT Oncology , CEO & Founder , NEXT Oncology

NOVEL PAYLOADS

Identification of Novel Payloads and Payload Combinations for Next-Generation ADCs

Photo of Tara Arvedson, PhD, CSO, Hexagon Bio , CSO , Hexagon Bio
Tara Arvedson, PhD, CSO, Hexagon Bio , CSO , Hexagon Bio
Photo of WonGyun Ahn, PhD, Associate Director Pharmacology, Pharmacology, Qurient Co., Ltd. , Assoc Dir Pharmacology , Pharmacology , Qurient Co., Ltd.
WonGyun Ahn, PhD, Associate Director Pharmacology, Pharmacology, Qurient Co., Ltd. , Assoc Dir Pharmacology , Pharmacology , Qurient Co., Ltd.

Despite substantial ADC pipeline growth, most clinically advanced and approved ADCs still rely on a narrow set of cytotoxic mechanisms, primarily microtubule inhibition and DNA damage. This presentation introduces a proteasome inhibitor (PI)-ADC platform that delivers a differentiated mechanism and retains activity in tumor models resistant to topoisomerase inhibitor–based ADCs. Examples across HER2, EGFR, CD38, and CD19 will demonstrate its potential to address resistance and expand next-generation ADC development.

MULTI-TARGETS, MULTI-PAYLOADS

A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance

Photo of Yonghao Zhao, PhD, Head of Biologics, R&D, Chengdu Kanghong Biotechnology Co.,Ltd. , Head of Biologics , R&D , Chengdu Kanghong Biotechnology Co.,Ltd.
Yonghao Zhao, PhD, Head of Biologics, R&D, Chengdu Kanghong Biotechnology Co.,Ltd. , Head of Biologics , R&D , Chengdu Kanghong Biotechnology Co.,Ltd.
Photo of Bruce Keyt, PhD, CSO, MultiValent Biotherapies, Inc. , CSO , MultiValent Biotherapies, Inc.
Bruce Keyt, PhD, CSO, MultiValent Biotherapies, Inc. , CSO , MultiValent Biotherapies, Inc.
Photo of Musheng Bao, PhD, Head, Oncology Biology, Changchun GeneScience Pharmaceutical Co Ltd GenSci , SVP, Head , Oncology Biology , Changchun GeneScience Pharmaceutical Co Ltd GenSci
Musheng Bao, PhD, Head, Oncology Biology, Changchun GeneScience Pharmaceutical Co Ltd GenSci , SVP, Head , Oncology Biology , Changchun GeneScience Pharmaceutical Co Ltd GenSci

GenSci180 is a novel bispecific ADC targeting CDH17 and CEACAM5, designed to treat CRC. Dual targeting enhances tumor response and durability while overcoming tumor heterogeneity and single-antigen resistance. The proprietary cleavable linker combines high plasma stability with effective payload release, aiming to balance potent tumor killing with improved safety. We will present pilot tox study data supporting further preclinical development and therapeutic evaluation.

NOVEL MOAs & ALTERNATIVE PLATFORMS

ADC Sequencing is the Next Major Development Challenge: Do Logic-Gated Bispecific ADCs Offer the Solution?

Photo of Kanupriya Kusumakar, MBBS, M.D, MMSc., Sr Principal Scientist, BiVictriX Therapeutics Ltd , Sr Principal Scientist , Biology , BiVictriX Therapeutics Ltd
Kanupriya Kusumakar, MBBS, M.D, MMSc., Sr Principal Scientist, BiVictriX Therapeutics Ltd , Sr Principal Scientist , Biology , BiVictriX Therapeutics Ltd
Photo of Cody Desjardins, PhD, Director, Neuromuscular Research, Dyne Therapeutics Inc. , Director , Neuromuscular Research , Dyne Therapeutics Inc
Cody Desjardins, PhD, Director, Neuromuscular Research, Dyne Therapeutics Inc. , Director , Neuromuscular Research , Dyne Therapeutics Inc
Photo of Joseph W. Lewcock, PhD, CSO & Head, Discovery, Denali Therapeutics Inc. , CSO & Head , Discovery , Denali Therapeutics Inc
Joseph W. Lewcock, PhD, CSO & Head, Discovery, Denali Therapeutics Inc. , CSO & Head , Discovery , Denali Therapeutics Inc
Photo of Adnan O. Abu-Yousif, PhD, Executive Director, Oncology Drug Discovery Unit; Takeda Pharmaceutical Co. Ltd. , Executive Director, Oncology Drug Discovery Unit , Research , Takeda Pharmaceutical Co Ltd
Adnan O. Abu-Yousif, PhD, Executive Director, Oncology Drug Discovery Unit; Takeda Pharmaceutical Co. Ltd. , Executive Director, Oncology Drug Discovery Unit , Research , Takeda Pharmaceutical Co Ltd
Photo of Caitlyn Miller, PhD, CEO & Co-Founder, TwoStep Therapeutics , Co-Founder & CEO , TwoStep Therapeutics
Caitlyn Miller, PhD, CEO & Co-Founder, TwoStep Therapeutics , Co-Founder & CEO , TwoStep Therapeutics
Photo of Zhigang Weng, PhD, Vice President & Head, Biology, Mariana Oncology, a Novartis Company , VP & Head of Biology , Biology , Mariana Oncology, a Novartis Company
Zhigang Weng, PhD, Vice President & Head, Biology, Mariana Oncology, a Novartis Company , VP & Head of Biology , Biology , Mariana Oncology, a Novartis Company
Photo of James Carroll, MBA, President & CEO, RNA Nanobiotics , President & CEO , RNA Nanobiotics
James Carroll, MBA, President & CEO, RNA Nanobiotics , President & CEO , RNA Nanobiotics

RNA NanoBiotics is advancing a programmable RNA nanostructure platform designed to deliver multiple chemotherapeutics and RNA interference (RNAi) therapeutics within a single targeted construct, enabling controlled sequential intracellular release. Supported by published preclinical efficacy and safety data, the platform is being developed for colorectal cancer through a staged progression from single-agent SN-38 delivery to dual- and triple-payload combinations. This presentation explores a multifunctional therapeutic architecture beyond conventional ADCs and multispecific antibodies.


For more details on the conference, please contact:
Mimi Langley
Executive Director, Conferences
Cambridge Healthtech Institute
Email: [email protected]

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Email: [email protected]

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-1340
Email: [email protected]


Register

View By:


Premier Sponsors

Biointron_new       Kactus